| M12 cohort (N = 59) | M24 cohort (N = 27) |
---|---|---|
HIV RNA < 400 copies/mL (%; 95% CI) | 35 (59.3; 46.1-71.3) | 9 (33.3; 17.5-54.0) |
HIV RNA 400-999 copies/mL (%; 95% CI) | 7 (11.9; 5.6-23.3) | 1 (3.7; 0.5-24.5) |
HIV RNA ≥ 1,000 copies/mL (%; 95% CI) | 17 (28.8; 18.5-42.0) | 17 (62.9; 42.5-79.7) |
   Available genotypic resistance (%) | 17 (100) | 17 (100) |
   Wild type virus (%) | 3 (17.6) | 1 (5.9) |
   Resistance to ≥ 1 ARV drug (%) | 13 (76.5) | 16 (94.1) |
   Resistance to EFV and NVP (%) | 0 (0) | 0 (0) |
   Resistance to 3TC, EFV and NVP (%) | 12 (70.6) | 6 (35.3) |
   Extensive resistancea (%) | 0 (0) | 8 (47.1) |